芪苈强心胶囊联合左西孟旦治疗急性心肌梗死合并心力衰竭患者的效果

Effects of Qili Qiangxin capsules combined with Levosimendan in treatment of acute myocardial infarction complicated with heart failure

目的:观察芪苈强心胶囊联合左西孟旦治疗急性心肌梗死合并心力衰竭患者的效果。方法:选取2022年1月至2023年1月该院收治的110例急性心肌梗死合并心力衰竭患者进行前瞻性研究,按照随机数字表法将其分为研究组和对照组各55例。对照组采用左西孟旦治疗,研究组在对照组基础上联合芪苈强心胶囊治疗。比较两组临床疗效、治疗前后血清学指标[可溶性致癌抑制因子2(sST2)、基质金属蛋白酶-9(MMP-9)]水平、心功能指标[左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)、左心室射血分数(LVEF)]水平及不良反应发生率。结果:研究组治疗总有效率为94.55%(52/55),高于对照组的81.82%(45/55),差异有统计学意义(P<0.05);治疗后,两组sST2、MMP-9水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组LVEF水平均高于治疗前,且研究组高于对照组,两组LVESD、LVESV水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率为9.09%(5/55),低于对照组的25.45%(14/55),差异有统计学意义(P<0.05)。结论:芪苈强心胶囊联合左西孟旦治疗急性心肌梗死合并心力衰竭患者,可提高临床疗效,降低sST2、MMP-9水平,改善心功能,降低不良反应发生率,效果优于单纯左西孟旦治疗。

Objective:To observe effects of Qili Qiangxin capsules combined with Levosimendan in treatment of acute myocardial infarction complicated with heart failure.Methods:A prospective study was conducted on 110 patients with acute myocardial infarction complicated with heart failure admitted to the hospital from January 2022 to January 2023.According to the random number table method,they were divided into study group and control group,55 cases in each group.The control group was treated with Levosimendan,while the study group was treated with Qili Qiangxin capsules on the basis of that of the control group.The clinical efficacy,the serological indexes[soluble carcinogenic suppressor 2(sST2),matrix metalloproteinase-9(MMP-9)]levels,the cardiac function indexes[left ventricular end-diastolic volume(LVEDV),left ventricular end-systolic volume(LVESV),left ventricular ejection fraction(LVEF)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 94.55%(52/55),which was higher than 81.82%(45/55)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of sST2 and MMP-9 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The LVEF levels of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the levels of LVESD and LVESV in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions in the study group was 9.09%(5/55),which was lower than 25.45%(14/55)in the control group,and the difference was statistically significant(P<0.05).Conclusions:Qili Qiangxin capsules combined with Levosimendan in the treatment of the patients with acute myocardial infarction complicated with heart failure can improve the clinical efficacy,reduce the levels of sST2 and MMP-9,improve the cardiac function,and reduce the incidence of adverse reactions.Moreover,it is superior to single Levosimendan treatment.